Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Providence Health & Services
University of Texas Southwestern Medical Center
Dragonfly Therapeutics
Bristol-Myers Squibb
Replimune Inc.
Myeloid Therapeutics
Dana-Farber Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute
University of Kansas Medical Center
Dana-Farber Cancer Institute
Bolt Biotherapeutics, Inc.
Mayo Clinic
Daiichi Sankyo
Compugen Ltd
Bristol-Myers Squibb
Eli Lilly and Company
Astellas Pharma Inc
Memorial Sloan Kettering Cancer Center
Oslo University Hospital
The Netherlands Cancer Institute
OHSU Knight Cancer Institute
Centre Leon Berard
NYU Langone Health
Fondazione per la Medicina Personalizzata
Fate Therapeutics
Fate Therapeutics
Jules Bordet Institute
Bristol-Myers Squibb
Bristol-Myers Squibb
The Netherlands Cancer Institute
The Netherlands Cancer Institute
Dana-Farber Cancer Institute
ExcellaBio LLC
Seoul National University Hospital
Odonate Therapeutics, Inc.
Istituto Oncologico Veneto IRCCS
Northwestern University
Celgene
National Cancer Institute (NCI)